long intergenic non-protein coding RNA 1841Genealiases: []
Q-omics provides the consensus-scored LINC01841 profile across patient tissues and cancer cell-line models. LINC01841 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01841 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, LINC01841 RNA expression shows 12,471 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where LINC01841 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01841 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01841 survival associations across molecular data types. LINC01841 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01841 RNA expression–survival associations across cancer types. High LINC01841 expression shows unfavorable associations in ACC, KIRC, LGG and LUSC, but favorable associations in LUAD and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01841 RNA expression.
This table summarizes LINC01841 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01841. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01841 shows lower tumor expression in LUSC, BLCA and KICH and higher tumor expression in HNSC, KIRC and THCA. The HNSC box plot shows higher LINC01841 RNA expression in tumor versus normal tissue (log2 FC = +0.103, t-test p = .003).
This table shows molecular features associated with LINC01841 in patient tissues and cancer cell lines. In patient samples, LINC01841 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
